ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2014

Abstract Number: 2433

Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Fabiola Atzeni1,2, Alessandra Monguzzi3, Elisabetta Grillo3, Luigi Lanata3 and Piercarlo Sarzi-Puttini2, 1V Giovanni Battista Grassi 74, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 2Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 3Medical Department, Dompé SpA, Milan, Italy

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: Ibuprofen, Inflammation, meta-analysis, pain management and rheumatoid arthritis (RA)

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ARHP): Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Patients with rheumatic diseases, including rheumatoid arthritis (RA), describe symptoms such as pain and stiffness as important factors affecting their quality of life. The most widely used drugs to decrease inflammation and manage mild-to-moderate pain in RA patients are NSAIDs. In our previous meta-analysis, we demonstrated that ketoprofen was superior to ibuprofen and/or diclofenac in relieving different kinds of moderate-to-severe pain conditions, and so the aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the clinical efficacy of these drugs in patients with the specific pain associated with RA.

Methods: We made a systematic search of the Medline and Embase databases from their inception to March 2014 in accordance with the Cochrane Collaboration guideline in order to identify RCTs directly comparing the recommended therapeutic doses of oral ketoprofen (50-200 mg/day), ibuprofen (600-1800 mg/day) and diclofenac (75-150 mg/day) for RA pain relief. The meta-analysis was made using the standardized mean difference (SMD) of each included RCT and a fixed effects model.

Results: Five RCTs, involving a total of 456 patients met the inclusion criteria. The meta-analysis showed a statistically significant difference in clinical efficacy in favour of ketoprofen (SMD= 0.34; CI 95% 0.16-0.52; p=0.0002). The heterogeneity test for the efficacy outcome was not statistically significant and equal to zero (χ2=3.67 – df=4 – P=0.45 – I2=0%), thus demonstrating the homogeneity of the trials and the validity of the meta-analysis findings. The meta-analysis did not reveal any significant differences between drugs in terms of tolerability (the percentage of patients developing adverse events) or safety (withdrawn patients).

Conclusion: The result of this meta-analysis shows that therapeutic doses of ketoprofen are more efficacious than ibuprofen and diclofenac in managing RA-related pain, thus supporting its use in clinical practice.


Disclosure:

F. Atzeni,
None;

A. Monguzzi,

Dompè SpA,

3;

E. Grillo,

Dompè SpA,

3;

L. Lanata,

Dompè SpA,

3;

P. Sarzi-Puttini,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-ketoprofen-vs-ibuprofen-and-diclofenac-for-treating-pain-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology